Patient characteristics
| Characteristic . | ISIS 3521 . | ISIS 5132 . | Total . | |||
|---|---|---|---|---|---|---|
| Number of patients | 14 | 16 | 30 | |||
| Median age (range) | 72 (58–78) | 66 (52–81) | 69 (52–81) | |||
| Performance status | ||||||
| 0 | 10 | 7 | 17 | |||
| 1 | 4 | 9 | 13 | |||
| Previous therapy | ||||||
| Radiation therapy | 9 | 10 | 19 | |||
| Surgical castration | ||||||
| LHRH agonist | ||||||
| Time from diagnosis to study entry | ||||||
| 12–24 months | 3 | 0 | 3 | |||
| >24 months | 11 | 16 | 27 | |||
| Sites of disease | ||||||
| Bone | 12 | 14 | 26 | |||
| Lymph nodes | 4 | 6 | 10 | |||
| Prostate | 1 | 1 | 2 | |||
| Measurable disease | ||||||
| Bidimensional | 4 | 6 | 10 | |||
| Nonmeasurable | 10 | 10 | 20 | |||
| Baseline PSA value (ng/ml) | ||||||
| <50 | 1 | 3 | 4 | |||
| 50–99 | 4 | 4 | 8 | |||
| 100–199 | 2 | 3 | 5 | |||
| 200–399 | 3 | 4 | 7 | |||
| ≥400 | 4 | 2 | 6 | |||
| Characteristic . | ISIS 3521 . | ISIS 5132 . | Total . | |||
|---|---|---|---|---|---|---|
| Number of patients | 14 | 16 | 30 | |||
| Median age (range) | 72 (58–78) | 66 (52–81) | 69 (52–81) | |||
| Performance status | ||||||
| 0 | 10 | 7 | 17 | |||
| 1 | 4 | 9 | 13 | |||
| Previous therapy | ||||||
| Radiation therapy | 9 | 10 | 19 | |||
| Surgical castration | ||||||
| LHRH agonist | ||||||
| Time from diagnosis to study entry | ||||||
| 12–24 months | 3 | 0 | 3 | |||
| >24 months | 11 | 16 | 27 | |||
| Sites of disease | ||||||
| Bone | 12 | 14 | 26 | |||
| Lymph nodes | 4 | 6 | 10 | |||
| Prostate | 1 | 1 | 2 | |||
| Measurable disease | ||||||
| Bidimensional | 4 | 6 | 10 | |||
| Nonmeasurable | 10 | 10 | 20 | |||
| Baseline PSA value (ng/ml) | ||||||
| <50 | 1 | 3 | 4 | |||
| 50–99 | 4 | 4 | 8 | |||
| 100–199 | 2 | 3 | 5 | |||
| 200–399 | 3 | 4 | 7 | |||
| ≥400 | 4 | 2 | 6 | |||